Roche says its C5 inhibitor aced PhIII head-to-head trials with AstraZeneca’s Soliris
One of the new drugs Roche is banking on for a 2023 launch has cleared two Phase III trials, the company reported.
Roche’s Genentech tested crovalimab, a C5 inhibitor, in two different groups of patients with the rare blood disorder paroxysmal nocturnal hemoglobinuria and reached two conclusions: Firstly, its drug works just as well as AstraZeneca’s blockbuster Soliris, a current standard of care, among patients who have not been treated with complement inhibitors; and secondly, it’s safe for patients to switch from currently approved C5 inhibitors to crovalimab.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.